Extranodal NK/T-Cell Lymphoma: Toward the Identification of Clinical Molecular Targets

Table 2

Potential Therapeutic targets for extranodal NKTCL.

Pathways	Genes	Expression	Chromosomal location	References
EBV	LMP2-TR	Up	N.A.	[32]
Survival/apoptosis
	CCND3	Down	6p21.1	[69]
	SERPINB9	Down	6p25	[19, 57]
	FASL	Up	1q23	[60, 78]
	TNFAIP3	Down	6q23	[69, 79]
Cell signaling pathways
JAK-STAT	STAT3	Up	17q21	[80, 81]
	JAK2	Up	9p24	[69, 81]
	IL10	Up	1q31-q32	[81, 82]
AKT	AKT1/2/3	Up	14q32.3/19q13.1/1q44	[69, 70]
NOTCH	NOTCH1	Up	9q34.3	[24, 83]
WNT	β-CATENIN	Up	3p22–p21.3	[24, 69]
PDGF	PDGFRA	Up	4q11–q13	[69]
	PDGFA/B	Up	7p22/22q12.3–q13.1	[69]
Angiogenesis
	HGFR (MET)	Up	7q31	[78]
	VEGFR2	Up	4q12	[24, 69]
	VEGFA	Up	6q12	[24, 69]
	HIF1α	Up	14q21–q24	[24, 70, 84]
Tumor suppressor genes
del6q21	PRDM1	Down	6q21–q22.1	[70]
	ATG5	Down	6q21	[70]
	AIM1	Down	6q21	[70]
	HACE1	Down	6q21	[69, 85]
Other pathways/genes
	TP53	Down	17p13.1	[86, 87]
	TP73	Down	1p36.3	[88]
	AURKA	Up	20q13	[24, 89]

N.A.: not applicable.